|Bid||108.5100 x 800|
|Ask||109.3400 x 800|
|Day's Range||105.5600 - 109.1912|
|52 Week Range||51.0500 - 133.7400|
|Beta (3Y Monthly)||2.56|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 12, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||137.70|
President & CEO of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) Mark Pruzanski sold 50,000 shares of ICPT on 11/16/2018 at an average price of $101.07 a share.
NEW YORK, NY / ACCESSWIRE / November 16, 2018 / U.S. equities regained footing on Thursday as oil prices climbed and hopes of a trade agreement between the U.S. and China raised investor’s optimism. The ...
Pharma stocks can serve as a profitable addition to investment portfolios. With 10,000 baby boomers aging into Medicare every day, and a Medicare Part D drug plan to subsidize the cost, demographics and government subsidies has created a virtuous cycle for healthcare stocks. As a result, some have seen price levels that its profits (assuming they exist) cannot sustain. Additionally, biotech stocks are inherently risky due to the process of drug development and approval.
NEW YORK, NY / ACCESSWIRE / November 8, 2018 / U.S. markets advanced on Wednesday as the midterm election results went according to market expectations. The Democrats took over the House, while the Republicans ...
NEW YORK, Nov. 05, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.
Intercept (ICPT) delivered earnings and revenue surprises of 17.74% and 0.76%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The New York-based company said it had a loss of $2.18 per share. The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of ...
Intercept Pharmaceuticals Inc. shares rose 3.2% in Wednesday premarket trade after the company reported a narrower-than-expected third-quarter loss. Intercept Pharma reported a net loss of $64.5 million, or a loss of $2.18 per share, after a loss of $72.6 million, or a loss of $2.89 per share in the year-earlier period. The FactSet adjusted earnings-per-share consensus was a loss of $2.56. Revenue rose to $46.99 million from $41.33 million, compared with the FactSet consensus of $48.2 million. Ocaliva sales rose to $46.6 million from $40.9 million, below the FactSet consensus of $47 million. Intercept Pharma still expects early results from its phase 3 trial testing Ocaliva in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) in the first half of next year. The company continues to expect 2018 net sales for its Ocaliva therapy of between $170 million and $185 million, in line with the FactSet consensus of $177.8 million. Intercept shares have dropped 4.3% over the last three months, compared with a 4.8% drop in the S&P 500 and a 2.1% decline in the Dow Jones Industrial Average .
Worldwide Ocaliva net sales of $46.6 million in the third quarter of 2018Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver.
Short interest is moderately high for ICPT with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on October 25.
NEW YORK, Oct. 24, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to.
NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
For whatever the reason — the trade war, Federal Reserve or general market malaise — investors have turned on a variety high-momentum shares. The rout in biotech stocks has been pretty severe. The iShares NASDAQ Biotechnology Index (NYSEARCA:IBB) — the broad sector benchmark — is down roughly 5% in October.
This upstart is developing a diagnostic test and treatment for nonalcoholic steatohepatitis, or NASH, an increasingly common liver disease.
Gilead's high-flying days are seemingly over. Intercept Pharmaceuticals, on the other hand, is only getting started.